OBJECTIVE: A phase II study was conducted to evaluate the anti-tumor activity and adverse effects of weekly docetaxel in patients with previously treated endometrial cancer. METHODS: Eligible patients were to have measurable disease with no more than one prior chemotherapy regimen. Docetaxel 36 mg/m(2) was administered intravenously over 1 h on days 1, 8 and 15. Cycles were repeated every 28 days until progression of disease or adverse effects prohibited further therapy. RESULTS: Twenty-seven patients were entered onto this study, of whom 26 were eligible and evaluable. All patients had received prior platinum with twenty (76.9%) having received prior treatment with paclitaxel. There were two (7.7%) partial responses, eight patients (30.8%) with stable disease, and fourteen patients (53.8%) with increasing disease. The most frequently reported adverse events were leucopenia, neutropenia, gastrointestinal, constitutional and peripheral neuropathy. Grade 3 and 4 adverse events were uncommon. CONCLUSIONS: Docetaxel, at the dose and schedule tested, has modest activity in this patient population.
OBJECTIVE: A phase II study was conducted to evaluate the anti-tumor activity and adverse effects of weekly docetaxel in patients with previously treated endometrial cancer. METHODS: Eligible patients were to have measurable disease with no more than one prior chemotherapy regimen. Docetaxel 36 mg/m(2) was administered intravenously over 1 h on days 1, 8 and 15. Cycles were repeated every 28 days until progression of disease or adverse effects prohibited further therapy. RESULTS: Twenty-seven patients were entered onto this study, of whom 26 were eligible and evaluable. All patients had received prior platinum with twenty (76.9%) having received prior treatment with paclitaxel. There were two (7.7%) partial responses, eight patients (30.8%) with stable disease, and fourteen patients (53.8%) with increasing disease. The most frequently reported adverse events were leucopenia, neutropenia, gastrointestinal, constitutional and peripheral neuropathy. Grade 3 and 4 adverse events were uncommon. CONCLUSIONS:Docetaxel, at the dose and schedule tested, has modest activity in this patient population.
Authors: Kathleen N Moore; Michael W Sill; Meaghan E Tenney; Christopher J Darus; David Griffin; Theresa L Werner; Peter G Rose; Robert Behrens Journal: Gynecol Oncol Date: 2015-07-11 Impact factor: 5.482
Authors: Melissa A Geller; Joseph J Ivy; Rahel Ghebre; Levi S Downs; Patricia L Judson; Linda F Carson; Amy L Jonson; Kathryn Dusenbery; Rachel Isaksson Vogel; Matthew P Boente; Peter A Argenta Journal: Gynecol Oncol Date: 2011-01-15 Impact factor: 5.482
Authors: Rachel Nicole Grisham; Christina Adaniel; David M Hyman; Weining Ma; Alexia Iasonos; Carol Aghajanian; Jason Konner Journal: Int J Gynecol Cancer Date: 2012-06 Impact factor: 3.437
Authors: Yu-Ping Liu; Jiahu Wang; Victoria A Avanzato; Jamie N Bakkum-Gamez; Stephen J Russell; John C Bell; Kah-Whye Peng Journal: Gynecol Oncol Date: 2014-01-14 Impact factor: 5.482
Authors: Don S Dizon; John A Blessing; D Scott McMeekin; Sudarshan K Sharma; Paul Disilvestro; Ronald D Alvarez Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Maria M Rubinstein; David M Hyman; Imogen Caird; Helen Won; Krysten Soldan; Kenneth Seier; Alexia Iasonos; William P Tew; Roisin E O'Cearbhaill; Rachel N Grisham; Martee L Hensley; Tiffany Troso-Sandoval; Paul Sabbatini; Joyce Guillen; S Duygu Selcuklu; Catherine Zimel; Jean Torrisi; Carol Aghajanian; Vicky Makker Journal: Cancer Date: 2019-12-27 Impact factor: 6.860